Home » Neuralight Hit With Warning Letter for Testing Without IND Approval
Neuralight Hit With Warning Letter for Testing Without IND Approval
Neuralight has earned a warning letter from the FDA for testing an investigational drug on human subjects without IND approval.
A May investigation revealed that the company administered the unapproved product to 20 subjects without going through the formal IND application process.
“By exposing human subjects to a new, unapproved drug without obtaining an IND, Neuralight jeopardized the safety of those subjects,” the letter chides.
Upcoming Events
-
07May
-
14May
-
30May